Janssen Pharmaceutica

China's Infliximab Market Investigation Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Genetics, Health, Oncology, Drugs, Monoclonal antibodies, Immunosuppressants, TNF inhibitors, Janssen Pharmaceutica, Infliximab, Janssen Biotech, Economy of China, China

The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • By 2020, Janssen Biologics BV is the only manufacturer in the Chinese Infliximab market.
  • According to the market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend.
  • 2 Sales of Infliximab in China, 2016-2020
    2.3 Sales of Infliximab by Dosage Form in China, 2016-2020
    3 Analysis of Major Infliximab Manufacturers in China, 2016-2020
    4 Prices of Infliximab for Different Manufacturers in China, 2020-2021
    5 Prospect of Chinese Infliximab drug Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005802/en/

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Rocket, 360 DigiTech, and Piedmont Lithium and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 29, 2021
Chemistry, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Euphoriants, Sufentanil, Fentanyl, Lithium

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • OnFebruary 16, 2021, AcelRx disclosed that, onFebruary 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.
  • For more information on the Piedmont Lithium class action go to: https://bespc.com/cases/PLL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 22, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter

Retrieved on: 
Tuesday, July 20, 2021
Drugs, Life sciences, Health care, Immunosuppressants, TNF inhibitors, Biotechnology, Monoclonal antibodies, Infliximab, Janssen Pharmaceutica, Biopharmaceutical, Biologics license application, National Medical Products Administration

China National Medical Product Administration (NMPA) has granted Mabpharm approval to marketINFLIXIMAB biobetter in China.

Key Points: 
  • China National Medical Product Administration (NMPA) has granted Mabpharm approval to marketINFLIXIMAB biobetter in China.
  • Sorrento holds commercialization rights outside of China and intends to meet with regulatory agencies to determine best path to registration for the US and Europe.
  • SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm Ltd (HK:2181) has received approval of its New Drug Application for its infliximab biobetter antibody in China.
  • Sorrento holds exclusive commercial rights to this product outside of China and plans to file a Biologics License Application (BLA) for the infliximab biobetter antibody in the United States and Europe in 2021.

Bereaved Parents Create Non-Profit to Combat Fentanyl Epidemic

Retrieved on: 
Sunday, July 18, 2021
Psychoactive drugs, Anilides, Piperidines, Synthetic opioids, Drugs, Chemical compounds, Designer drugs, Janssen Pharmaceutica, Fentanyl

Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .

Key Points: 
  • Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .
  • "Educating kids and families about the real dangers of fentanyl is just as important as monitoring platforms for drug activity.
  • In addition, Snap will also run a special episode of its award-winning news show, Good Luck America (GLA), devoted to the fentanyl epidemic and featuring an interview with Ed Ternan.
  • "We are honored to partner with Song for Charlie to educate young people on the dangers of counterfeit drugs and fentanyl poisoning.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 15, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 8, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, July 1, 2021
Legal, Professional services, Opioids, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Euphoriants, Fentanyl, Sufentanil

AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • If you suffered a loss due to AcelRx Therapeutics, Inc.'s misconduct, click here .
  • On February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 1, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Ethers, Sufentanil, Fentanyl

AcelRx is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.

Key Points: 
  • AcelRx is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • OnFebruary 16, 2021, AcelRx disclosed that, onFebruary 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.
  • For more information on the Tarena class action go to: https://bespc.com/cases/TEDU
    About Bragar Eagel & Squire, P.C.

Investigation Report on China's Levofloxacin Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021
Infectious diseases, Pharmaceutical, Health, Drugs, Fluoroquinolone antibiotics, Health sciences, Health care, Enantiopure drugs, Janssen Pharmaceutica, Levofloxacin, Sanofi, Daiichi Sankyo, Ofloxacin, Economy of China, Pharmaceutical industry

The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Levofloxacin tablets were approved in China in 1995, and Levofloxacin injection and oral regular-release liquids have entered China's medical insurance.
  • By the half-past of 2021, there are many manufacturers in China's Levofloxacin market, among which Daiichi Sankyo Pharmaceutical (Beijing) accounts for the highest proportion of market share.
  • According to the market research, the sales value of Levofloxacin in the Chinese market from 2016 to 2019 has shown an overall upward trend.